126 related articles for article (PubMed ID: 9218022)
1. Re-examining the role of prostate-specific antigen density in predicting outcome for clinically localized prostate cancer.
Ingenito AC; Ennis RD; Hsu IC; Begg MD; Benson MC; Schiff PB
Urology; 1997 Jul; 50(1):73-8. PubMed ID: 9218022
[TBL] [Abstract][Full Text] [Related]
2. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
3. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
4. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
5. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
6. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
[TBL] [Abstract][Full Text] [Related]
7. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
[TBL] [Abstract][Full Text] [Related]
8. Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors.
D'Amico AV; Schultz D; Schneider L; Hurwitz M; Kantoff PW; Richie JP
J Urol; 2000 Jun; 163(6):1797-801. PubMed ID: 10799185
[TBL] [Abstract][Full Text] [Related]
9. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
Copp H; Bissonette EA; Theodorescu D
Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
[TBL] [Abstract][Full Text] [Related]
10. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
11. Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer.
Nguyen PL; Whittington R; Koo S; Schultz D; Cote KB; Loffredo M; Tempany CM; Titelbaum DS; Schnall MD; Renshaw AA; Tomaszewski JE; D'Amico AV
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):400-5. PubMed ID: 15145155
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure.
Radwan MH; Yan Y; Luly JR; Figenshau RS; Brandes SB; Bhayani SB; Bullock AD; Liefu Y; Andriole GL; Kibel AS
Urology; 2007 Jun; 69(6):1121-7. PubMed ID: 17572199
[TBL] [Abstract][Full Text] [Related]
13. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
Zelefsky MJ; Ben-Porat L; Scher HI; Chan HM; Fearn PA; Fuks ZY; Leibel SA; Venkatraman ES
J Clin Oncol; 2005 Feb; 23(4):826-31. PubMed ID: 15681527
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
[TBL] [Abstract][Full Text] [Related]
15. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
Yu HH; Song DY; Tsai YY; Thompson T; Frassica DA; DeWeese TL
Urology; 2007 Jul; 70(1):111-6. PubMed ID: 17656219
[TBL] [Abstract][Full Text] [Related]
16. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ
J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824
[TBL] [Abstract][Full Text] [Related]
17. Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation.
Seaward SA; Weinberg V; Lewis P; Leigh B; Phillips TL; Roach M
Cancer J Sci Am; 1998; 4(6):370-7. PubMed ID: 9853136
[TBL] [Abstract][Full Text] [Related]
18. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
[TBL] [Abstract][Full Text] [Related]
19. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
Akyol F; Ozyigit G; Selek U; Karabulut E
Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer.
Brassell SA; Kao TC; Sun L; Moul JW
Urology; 2005 Dec; 66(6):1229-33. PubMed ID: 16360448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
